22S Stock Overview A medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Nuwellis, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Nuwellis Historical stock prices Current Share Price US$4.46 52 Week High US$51.45 52 Week Low US$4.13 Beta 0.43 1 Month Change 0% 3 Month Change -34.13% 1 Year Change -90.53% 3 Year Change -99.93% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024 Nov 02
Nuwellis, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 24
Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis Oct 22 Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million. Aug 27
Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million. Aug 24
Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions Aug 09
See more updates
Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024 Nov 02
Nuwellis, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 24
Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis Oct 22 Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million. Aug 27
Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million. Aug 24
Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions Aug 09
Nuwellis Announces First Pediatric Patient Treated in A Commercial Setting with Seastar Medical's Quelimune Therapy At Cincinnati Children's Jul 26 Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $1.990002 million. Jul 25
Nuwellis, Inc. to Report Q2, 2024 Results on Aug 13, 2024 Jul 24
Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's Jul 18
Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference Jul 10
Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement May 30
First quarter 2024 earnings released: US$0.78 loss per share (vs US$5.76 loss in 1Q 2023) May 08 Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health Apr 10
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days Mar 08
Full year 2023 earnings released: US$11.52 loss per share (vs US$83.48 loss in FY 2022) Mar 07
Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 28
Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter Jan 05
Nuwellis Receives Non-Compliance Notice from Nasdaq Dec 14
Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients Nov 29
Third quarter 2023 earnings released: US$1.81 loss per share (vs US$36.72 loss in 3Q 2022) Nov 08
New major risk - Revenue and earnings growth Nov 08
Less than half of directors are independent Nov 05
Nuwellis, Inc. Announces Board of Directors Transition Nov 02
Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 19 Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million. Oct 18
Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption Oct 11
Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023 Aug 19
Second quarter 2023 earnings released: US$3.65 loss per share (vs US$40.67 loss in 2Q 2022) Aug 09
Nuwellis, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 21
New major risk - Revenue and earnings growth Jul 13
Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors Jun 06
First quarter 2023 earnings released: US$5.76 loss per share (vs US$42.45 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$83.48 loss per share (vs US$287 loss in FY 2021) Mar 02
Nuwellis, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Nuwellis, Inc. Announces Board Changes Jan 19
Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 10
Nuwellis Appoints John Jefferies as Chief Medical Officer Jan 06
Nuwellis Announces Compliance with Nasdaq Listing Requirements Dec 28
Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement Dec 01
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.74 loss in 3Q 2021) Nov 09
Nuwellis, Inc. Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using A Modified Aquadex in Low-Birth-Weight Preterm Neonates Nov 04
Insufficient new directors Nov 01
Nuwellis, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 20 Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality At the 2022 Hfsa Meeting Oct 04
Insufficient new directors Oct 02
Nuwellis, Inc. Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial Sep 28
Nuwellis, Inc. Announces Executive Changes Sep 24
Nuwellis, Inc. Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients Sep 01
Nuwellis, Inc. Announces U.S. Patent and Trademark Office Awards Patent for Innovative Pediatric Technology Aug 26
Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.72 loss in 2Q 2021) Aug 11
Nuwellis, Inc Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA Jul 27
Nuwellis, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 15
Nuwellis, Inc. Announces First Patient Enrolled in Its Pivotal Trial REVERSE-HF Jun 30
Nuwellis Receives a Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement Jun 04
First quarter 2022 earnings released: US$0.42 loss per share (vs US$1.25 loss in 1Q 2021) May 11
Nuwellis, Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 13
Nuwellis, Inc., Annual General Meeting, May 17, 2022 Apr 12
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 03
Nuwellis, Inc. Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload Feb 18
Nuwellis, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 02
Nuwellis, Inc. Provides Revenue Guidance for the Full Year 2021 Aug 12
Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology May 14
CHF Solutions Submits Patent Application for New Peripheral Venous Access Technology for Ultrafiltration and CRRT Systems Mar 12
Chf Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Puerto Rico Mar 11
CHF Solutions, Inc. to Report Q4, 2020 Results on Mar 02, 2021 Feb 17
CHF Solutions, Inc. Submits Patent Application for New and Improved Diagnostic Parameters to Support Hemodynamic Stability Feb 04
CHF Solutions, Inc. Announces Executive Changes Jan 21
CHF Solutions, Inc. Submits Patent Application for A Peripheral Vascular Access Catheter Jan 13
CHF Solutions, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
CHF Solutions Announces Deployment of Aquadex Systems to Hospitals in the Southeast to Treat COVID-19 Patients Oct 29
CHF Solutions Announces Data Demonstrating Benefit of Aquadex Therapy for Treatment of Heart Failure and COVID-19 Oct 08
CHF Solutions Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement Sep 02
CHF Solutions, Inc. has completed a Composite Units Offering in the amount of $12.498388 million. Aug 20 Shareholder Returns 22S DE Medical Equipment DE Market 7D 0% -3.3% -2.0% 1Y -90.5% -8.5% 6.9%
See full shareholder returns
Return vs Market: 22S underperformed the German Market which returned 7.6% over the past year.
Price Volatility Is 22S's price volatile compared to industry and market? 22S volatility 22S Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 22S's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 22S's volatility change over the past year.
About the Company Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
Show more Nuwellis, Inc. Fundamentals Summary How do Nuwellis's earnings and revenue compare to its market cap? 22S fundamental statistics Market cap €2.17m Earnings (TTM ) -€20.46m Revenue (TTM ) €8.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 22S income statement (TTM ) Revenue US$9.01m Cost of Revenue US$3.58m Gross Profit US$5.43m Other Expenses US$28.25m Earnings -US$22.81m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -12.22 Gross Margin 60.28% Net Profit Margin -253.06% Debt/Equity Ratio 0%
How did 22S perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/09/24 07:21 End of Day Share Price 2024/06/27 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nuwellis, Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jan Wald Benchmark Company Sean Lavin BTIG Jason Mills Canaccord Genuity
Show 9 more analysts 
